Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ANAB

AnaptysBio Inc

Dec 26 • 04:00PM ET

13.74

Dollar change -0.15
Percentage change -1.08	%

Healthcare • Biotechnology • USA • NASD

Peers: REGN VRTX BMRN ALNY IONS SRPT EXEL BLUE INCY RGEN

| Held by: VTI XBI IWM VXF VB VBK IWO IBB VTWO SCHA

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-6.07	Insider Own	14.52%	Shs Outstand	30.43M	Perf Week	-10.43%
Market Cap	418.09M	Forward P/E	-	EPS next Y	-5.36	Insider Trans	5.32%	Shs Float	26.01M	Perf Month	-42.99%
Income	-165.66M	PEG	-	EPS next Q	-1.62	Inst Own	103.68%	Short Float	26.86%	Perf Quarter	-57.74%
Sales	57.17M	P/S	7.31	EPS this Y	-0.07%	Inst Trans	18.81%	Short Ratio	12.37	Perf Half Y	-44.60%
Book/sh	2.77	P/B	4.96	EPS next Y	11.84%	ROA	-33.78%	Short Interest	6.99M	Perf Year	-36.03%
Cash/sh	14.14	P/C	0.97	EPS next 5Y	-	ROE	-161.81%	52W Range	13.82 - 41.31	Perf YTD	-35.85%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-19.45%	ROI	-36.85%	52W High	-66.74%	Beta	-0.10
Dividend TTM	-	Quick Ratio	10.23	Sales past 5Y	172.96%	Gross Margin	95.80%	52W Low	-0.58%	ATR (14)	1.82
Dividend Ex-Date	-	Current Ratio	10.23	EPS Y/Y TTM	-12.12%	Oper. Margin	-245.01%	RSI (14)	29.32	Volatility	6.36% 9.59%
Employees	117	Debt/Eq	4.35	Sales Y/Y TTM	282.17%	Profit Margin	-289.75%	Recom	1.55	Target Price	33.90
Option/Short	Yes / Yes	LT Debt/Eq	4.33	EPS Q/Q	19.10%	Payout	-	Rel Volume	0.69	Prev Close	13.89
Sales Surprise	265.83%	EPS Surprise	30.78%	Sales Q/Q	804.67%	Earnings	Nov 05 AMC	Avg Volume	564.89K	Price	13.74
SMA20	-27.73%	SMA50	-39.84%	SMA200	-49.47%	Trades		Volume	388,489	Change	-1.08%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-11-24	Downgrade	H.C. Wainwright	Buy → Neutral	$52 → $19
Dec-02-24	Downgrade	BTIG Research	Buy → Neutral
Jul-22-24	Initiated	H.C. Wainwright	Buy	$55
Jul-19-24	Upgrade	JP Morgan	Neutral → Overweight	$29 → $69
Apr-16-24	Initiated	Leerink Partners	Outperform	$47
Apr-11-24	Initiated	Wells Fargo	Overweight	$56
Mar-12-24	Upgrade	Wedbush	Neutral → Outperform	$20 → $34
Feb-26-24	Initiated	BTIG Research	Buy	$55
Feb-21-24	Initiated	Stifel	Buy	$50
Feb-16-24	Initiated	Piper Sandler	Overweight	$80
May-22-23	Upgrade	JP Morgan	Underweight → Neutral	$31 → $30
May-18-23	Initiated	TD Cowen	Outperform
Jan-06-23	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-01-22	Upgrade	Guggenheim	Neutral → Buy	$44
Sep-19-22	Resumed	H.C. Wainwright	Buy	$35
Sep-13-22	Downgrade	Truist	Buy → Hold	$50 → $28
Sep-01-22	Initiated	Raymond James	Outperform	$35
Mar-22-22	Downgrade	Guggenheim	Buy → Neutral
Jun-22-21	Initiated	H.C. Wainwright	Buy	$43
May-21-21	Initiated	UBS	Neutral	$29

Show Previous Ratings

Dec-12-24 05:23AM	AnaptysBios atopic dermatitis trial of BTLA agonist misses endpoints (Clinical Trials Arena)
Dec-11-24 02:07PM	AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data (Benzinga) -32.83%
08:30AM	Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis (GlobeNewswire)
Nov-25-24 09:40AM	Are Medical Stocks Lagging AnaptysBio (ANAB) This Year? (Zacks) +8.22%
Nov-08-24 12:00PM	AnaptysBio (ANAB) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
09:35AM	Loading…
09:35AM	Down -32.84% in 4 Weeks, Here's Why You Should You Buy the Dip in AnaptysBio (ANAB) (Zacks)
Nov-05-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +11.72%
04:15PM	Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:15PM	Anaptys Announces Participation in November and December Investor Conferences (GlobeNewswire)
Aug-29-24 09:15AM	Anaptys Announces Participation in September Investor Conferences (GlobeNewswire)
Aug-23-24 07:26AM	Why AnaptysBio Was Such a Healthy Stock This Week (Motley Fool)
Aug-14-24 04:11PM	AnaptysBio Surges After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily) -6.35%
10:05AM	AnaptysBio Hits Five-Year High After Sanofi Takes A Stake In $100 Million Offering (Investor's Business Daily)
05:00AM	Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering (GlobeNewswire)
Aug-05-24 09:54PM	ANAB Stock Earnings: AnaptysBio Misses EPS, Misses Revenue for Q2 2024 (InvestorPlace)
05:55PM	Loading…
05:55PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:15PM	Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jul-29-24 10:00AM	AnaptysBio, Inc. (ANAB) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-22-24 02:53PM	AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst (Benzinga) +5.96%
May-09-24 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -10.75%
04:15PM	Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
04:10PM	Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
04:05PM	Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties (GlobeNewswire)
May-02-24 10:01AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
May-01-24 04:51AM	AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock? (Zacks) +6.90%
Apr-24-24 09:00AM	Actym Therapeutics Appoints Thomas Smart as CEO (PR Newswire)
Apr-15-24 02:19PM	BTIG Research Predicts Over 118% Rally for These 3 Stocks (InvestorPlace) -6.34%
Apr-12-24 07:00PM	Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week (Motley Fool) -8.17%
Apr-09-24 02:40PM	Why You Shouldn't Bet Against AnaptysBio (ANAB) Stock. (Zacks)
Mar-14-24 12:00PM	What Makes AnaptysBio, Inc. (ANAB) a New Buy Stock (Zacks)
09:55AM	Loading…
09:55AM	Wall Street Analysts Believe AnaptysBio, Inc. (ANAB) Could Rally 69.62%: Here's is How to Trade (Zacks)
Mar-11-24 05:30PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates (Zacks) -5.85% +11.61%
04:15PM	Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Feb-29-24 09:15AM	Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting (GlobeNewswire)
Feb-28-24 10:00AM	AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Feb-22-24 04:00AM	13 Best Short Squeeze Stocks To Buy Now (Insider Monkey)
Feb-19-24 05:54AM	Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength? (Zacks)
Jan-31-24 09:15AM	Anaptys to Present at Guggenheim's 6th Annual Biotechnology Conference (GlobeNewswire)
Jan-12-24 03:02PM	AnaptysBio Inc CEO Daniel Faga Sells 6,866 Shares (GuruFocus.com)
Dec-07-23 09:55AM	Does AnaptysBio, Inc. (ANAB) Have the Potential to Rally 69.36% as Wall Street Analysts Expect? (Zacks)
Nov-27-23 04:15PM	Anaptys Expands Immune Cell Modulator Pipeline with Exclusive License to BDCA2 Modulator Antibody Portfolio from Centessa Pharmaceuticals (GlobeNewswire)
Nov-14-23 09:35AM	Down -24.46% in 4 Weeks, Here's Why AnaptysBio, Inc. (ANAB) Looks Ripe for a Turnaround (Zacks) +7.29%
Nov-07-23 04:15PM	Anaptys Named a BioSpace 2024 Best Places to Work Winner (GlobeNewswire) -6.17%
Nov-04-23 05:41AM	AnaptysBio Inc (ANAB) Reports Q3 2023 Financial Results and Business Updates (GuruFocus.com)
Nov-02-23 04:15PM	Anaptys Announces Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) +8.21%
Nov-01-23 09:15AM	Anaptys Announces Participation in November Investor Conferences (GlobeNewswire)
Oct-11-23 09:15AM	Anaptys to Present Phase 1 Data on ANB032, its BTLA Agonist Antibody, at the 32nd EADV Congress (GlobeNewswire)
Oct-09-23 08:27AM	UPDATE 1-AnaptysBio's skin disease drug meets main goal in late-stage study (Reuters)
08:15AM	Anaptys to Provide Overview of Rosnilimab, a PD-1 Agonist, at Virtual R&D Event on Wednesday, Oct. 25 (GlobeNewswire)
08:05AM	AnaptysBio's skin disease drug meets main goal in late-stage study (Reuters)
08:00AM	Anaptys Announces Positive Top-Line Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
Sep-19-23 03:01PM	Insider Sell: Eric Loumeau Sells 6,000 Shares of AnaptysBio Inc (GuruFocus.com)
Sep-18-23 04:15PM	AnaptysBio Announces Appointment of John Orwin as Chairman of the Board of Directors (GlobeNewswire)
Sep-12-23 09:15AM	AnaptysBio to Present at the Stifel 2023 Immunology and Inflammation Virtual Summit (GlobeNewswire)
Aug-07-23 04:15PM	AnaptysBio Announces Second Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-23 01:34PM	AnaptysBio- and GSK-Partnered Immuno-Oncology Agent JEMPERLI (dostarlimab-gxly) plus Chemotherapy Approved in the U.S. for dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer (GlobeNewswire) +15.13%
Jul-04-23 06:22AM	Shareholders in AnaptysBio (NASDAQ:ANAB) are in the red if they invested five years ago (Simply Wall St.)
May-30-23 04:15PM	AnaptysBio Announces Participation in Upcoming Investor Conferences (GlobeNewswire)
May-24-23 06:01AM	Need To Know: The Consensus Just Cut Its AnaptysBio, Inc. (NASDAQ:ANAB) Estimates For 2023 (Simply Wall St.)
May-22-23 01:44AM	4 big analyst picks: Norfolk Southern stock pops on 2 upgrades (Investing.com)
May-11-23 05:35PM	AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.31%
04:15PM	AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update (GlobeNewswire)
May-04-23 09:55AM	Wall Street Analysts Predict a 45.12% Upside in AnaptysBio, Inc. (ANAB): Here's What You Should Know (Zacks)
May-02-23 09:15AM	AnaptysBio Announces British Journal of Dermatology Publication of Imsidolimab (IL-36R) Previously Reported Phase 2 GALLOP Data in Generalized Pustular Psoriasis (GPP) (GlobeNewswire)
Apr-30-23 09:47AM	When Will AnaptysBio, Inc. (NASDAQ:ANAB) Breakeven? (Simply Wall St.)
Apr-27-23 10:02AM	Cytokinetics (CYTK) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-26-23 10:02AM	Will AnaptysBio, Inc. (ANAB) Report Negative Q1 Earnings? What You Should Know (Zacks)
Apr-14-23 03:13AM	CRISPR Therapeutics AG (CRSP) Soars 16.3%: Is Further Upside Left in the Stock? (Zacks)
Apr-06-23 04:15PM	AnaptysBio Announces Appointment of Rita Jain, M.D., to Board of Directors (GlobeNewswire)
Apr-03-23 07:14AM	Companies Like AnaptysBio (NASDAQ:ANAB) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-27-23 06:50PM	AnaptysBio- and GSK-partnered immuno-oncology agent Jemperli (dostarlimab-gxly) plus chemotherapy demonstrates statistically significant and clinically meaningful improvement in progression-free survival for the treatment of primary advanced or recurrent endometrial cancer versus chemotherapy alone in Phase 3 RUBY trial (GlobeNewswire)
Mar-01-23 05:45PM	AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update (GlobeNewswire)
Feb-27-23 04:05PM	AnaptysBio to Participate at the Cowen and Company 43rd Annual Health Care Conference (GlobeNewswire)
Jan-13-23 09:00AM	AnaptysBio Announces Stock Repurchase Plan (GlobeNewswire) +14.35%
Jan-05-23 04:05PM	AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies (GlobeNewswire) -23.10%
Dec-22-22 09:33AM	The past five years for AnaptysBio (NASDAQ:ANAB) investors has not been profitable (Simply Wall St.)
Dec-02-22 09:00AM	AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer (GlobeNewswire)
Nov-21-22 01:56PM	AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire)
Nov-11-22 05:19AM	AnaptysBio Third Quarter 2022 Earnings: Misses Expectations (Simply Wall St.)
Nov-09-22 02:10PM	AnaptysBio to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Nov-08-22 05:55PM	AnaptysBio, Inc. (ANAB) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update (GlobeNewswire)
Oct-25-22 06:28AM	Here's Why We're Not Too Worried About AnaptysBio's (NASDAQ:ANAB) Cash Burn Situation (Simply Wall St.)
Oct-13-22 09:55AM	AnaptysBio, Inc. (ANAB) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) +5.68%
Oct-06-22 11:02AM	GSK's (GSK) PD-1 Inhibitor Drug Meets Lung Cancer Study Goal (Zacks)
Oct-05-22 11:31AM	AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial (Benzinga)
09:00AM	AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials (GlobeNewswire)
Sep-26-22 08:00AM	Phathom Pharmaceuticals Appoints Dr. James Topper to its Board of Directors (GlobeNewswire)
Sep-19-22 02:02PM	HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround (Benzinga)
Sep-14-22 06:14AM	New Forecasts: Here's What Analysts Think The Future Holds For AnaptysBio, Inc. (NASDAQ:ANAB) (Simply Wall St.)
Sep-12-22 11:18AM	AnaptysBio Sells Royalty Interest In Cancer Drug For $45M (Benzinga)
07:30AM	AnaptysBio Announces Sale of Zejula Royalties for Up To $45 Million (GlobeNewswire)
Sep-02-22 01:41PM	Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback (Benzinga)
Sep-01-22 09:58AM	AnaptysBio Faces Another Setback For Imsidolimab, Stalls Work In Skin Scarring Indication (Benzinga) +6.63%
Aug-31-22 04:15PM	AnaptysBio Reports HARP Phase 2 Top-Line Data of Imsidolimab in Moderate-to-Severe Hidradenitis Suppurativa (GlobeNewswire)
Aug-10-22 06:28AM	Analyst Forecasts Just Became More Bearish On AnaptysBio, Inc. (NASDAQ:ANAB) (Simply Wall St.)
Aug-08-22 05:35PM	AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.63%
04:05PM	AnaptysBio Announces Second Quarter 2022 Financial Results and Provides Pipeline Update (GlobeNewswire)
Aug-05-22 04:00PM	AnaptysBio to Participate at the 2022 Wedbush PacGrow Healthcare Virtual Conference (GlobeNewswire) +6.65%

AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the development of antibody product candidates. Its products pipeline include ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the natural process of somatic hypermutation embedded within the human immune system to rapidly develop a diverse range of therapeutic-grade antibodies in vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
RENTON HOLLINGS	Director	Nov 29 '24	Option Exercise	6.93	10,000	69,300	11,950	Dec 03 04:35 PM
RENTON HOLLINGS	Director	Nov 29 '24	Sale	25.00	10,000	250,000	1,950	Dec 03 04:35 PM
HOLLINGS C RENTON	Director	Nov 29 '24	Proposed Sale	25.00	10,000	250,000		Nov 29 01:29 PM
Lizzul Paul F.	Chief Medical Officer	Sep 23 '24	Option Exercise	18.50	1,500	27,750	16,898	Sep 24 04:18 PM
Lizzul Paul F.	Chief Medical Officer	Sep 23 '24	Sale	38.67	1,500	58,005	15,398	Sep 24 04:18 PM
PAUL F LIZZUL	Officer	Sep 23 '24	Proposed Sale	38.67	1,500	58,005		Sep 23 04:16 PM
Orwin John A	Director	Sep 15 '24	Option Exercise	0.00	1,300	0	3,335	Sep 17 06:45 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 16 '24	Option Exercise	14.02	5,000	70,100	13,520	Sep 17 06:44 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 14 '24	Option Exercise	0.00	6,000	0	10,740	Sep 17 06:44 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 16 '24	Sale	39.82	8,720	347,270	7,020	Sep 17 06:44 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Sep 17 '24	Sale	38.41	3,780	145,191	3,240	Sep 17 06:44 PM
Lizzul Paul F.	Chief Medical Officer	Sep 16 '24	Sale	38.93	2,220	86,425	15,398	Sep 17 06:42 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Sep 16 '24	Option Exercise	20.16	10,000	201,600	14,744	Sep 17 06:41 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Sep 16 '24	Sale	39.91	12,220	487,725	4,744	Sep 17 06:41 PM
ERIC J LOUMEAU	Officer	Sep 17 '24	Proposed Sale	38.41	3,780	145,191		Sep 17 04:02 PM
DENNIS MULROY	Officer	Sep 16 '24	Proposed Sale	40.13	10,000	401,300		Sep 16 04:33 PM
ERIC J LOUMEAU	Officer	Sep 16 '24	Proposed Sale	40.13	6,500	260,845		Sep 16 04:22 PM
Lizzul Paul F.	Chief Medical Officer	Aug 14 '24	Option Exercise	18.50	2,000	37,000	13,618	Aug 16 04:09 PM
Lizzul Paul F.	Chief Medical Officer	Aug 14 '24	Sale	40.00	2,000	80,000	11,618	Aug 16 04:09 PM
EcoR1 Capital, LLC	10% Owner	Aug 14 '24	Buy	36.50	273,972	9,999,978	7,794,996	Aug 16 12:04 PM
PAUL F LIZZUL	Officer	Aug 14 '24	Proposed Sale	40.00	2,000	80,000		Aug 14 04:34 PM
Lizzul Paul F.	Chief Medical Officer	Jul 18 '24	Option Exercise	18.50	1,500	27,750	13,118	Jul 19 08:35 PM
Lizzul Paul F.	Chief Medical Officer	Jul 18 '24	Sale	35.00	1,500	52,500	11,618	Jul 19 08:35 PM
RENTON HOLLINGS	Director	Jul 15 '24	Option Exercise	6.93	10,000	69,300	11,950	Jul 17 04:45 PM
RENTON HOLLINGS	Director	Jul 15 '24	Sale	30.64	10,000	306,422	1,950	Jul 17 04:45 PM
FENTON DENNIS M	Director	Jun 21 '24	Sale	23.17	1,950	45,182	1,950	Jun 24 05:23 PM
FENTON DENNIS M	Director	Jun 15 '24	Option Exercise	0.00	3,900	0	3,900	Jun 18 08:18 PM
Marquet Magda	Director	Jun 15 '24	Option Exercise	0.00	3,900	0	3,900	Jun 18 08:17 PM
Schmid John P.	Director	Jun 15 '24	Option Exercise	0.00	3,900	0	3,900	Jun 18 08:17 PM
Ware J. Anthony	Director	Jun 15 '24	Option Exercise	0.00	3,900	0	7,500	Jun 18 08:16 PM
Orwin John A	Director	Jun 15 '24	Option Exercise	0.00	2,035	0	2,035	Jun 18 08:15 PM
RENTON HOLLINGS	Director	Jun 15 '24	Option Exercise	0.00	3,900	0	3,900	Jun 18 08:15 PM
RENTON HOLLINGS	Director	Jun 18 '24	Sale	23.16	1,950	45,162	1,950	Jun 18 08:15 PM
Jain Rita	Director	Jun 15 '24	Option Exercise	0.00	4,534	0	4,534	Jun 18 08:14 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	May 22 '24	Sale	23.72	1,500	35,580	964	May 24 04:12 PM
Faga Daniel	CEO	Mar 22 '24	Sale	22.78	145,940	3,325,185	752,087	Mar 26 08:10 PM
Faga Daniel	CEO	Mar 25 '24	Sale	21.42	3,000	64,268	749,087	Mar 26 08:10 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Feb 16 '24	Option Exercise	14.02	5,000	70,100	8,240	Feb 21 05:38 PM
LOUMEAU ERIC J	CHIEF LEGAL OFFICER	Feb 16 '24	Sale	25.00	5,000	125,000	3,240	Feb 21 05:38 PM
MULROY DENNIS	CHIEF FINANCIAL OFFICER	Jan 30 '24	Sale	23.63	3,065	72,425	964	Feb 01 05:27 PM
Lizzul Paul F.	Chief Medical Officer	Jan 06 '24	Option Exercise	0.00	6,145	0	12,672	Jan 09 07:08 PM
Lizzul Paul F.	Chief Medical Officer	Jan 08 '24	Sale	21.81	2,554	55,703	10,118	Jan 09 07:08 PM
LOUMEAU ERIC J	Chief Legal Officer	Jan 06 '24	Option Exercise	0.00	5,545	0	5,545	Jan 09 07:07 PM
LOUMEAU ERIC J	Chief Legal Officer	Jan 08 '24	Sale	21.81	2,305	50,272	3,240	Jan 09 07:07 PM
MULROY DENNIS	Chief Financial Officer	Jan 06 '24	Option Exercise	0.00	5,245	0	6,209	Jan 09 07:06 PM
MULROY DENNIS	Chief Financial Officer	Jan 08 '24	Sale	21.81	2,180	47,546	4,029	Jan 09 07:06 PM
Faga Daniel	CEO	Jan 06 '24	Option Exercise	0.00	17,850	0	904,893	Jan 09 07:05 PM
Faga Daniel	CEO	Jan 08 '24	Sale	21.81	6,866	149,747	898,027	Jan 09 07:05 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ANAB

AnaptysBio Inc

Upgrade your FINVIZ experience